Published by Iain Gilbert on 6th June 2025
(Sharecast News) - Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens of its chronic lymphocytic leukaemia candidate Calquence in a first-line setting.
URL: http://www.digitallook.com/dl/news/story/35132286/...